Hutchison China MediTech, a CK Hutchison-backed pharmaceutical with a pipeline of immuno-oncology candidates, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Hong Kong-based company, which was founded in 2000 and booked $136 million in sales for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol HCM. Hutchison China MediTech initially filed confidentially on August 21, 2015. BofA Merrill Lynch and Deutsche Bank are the joint bookrunners on the deal. No pricing terms were disclosed.
